Anti-TNF-α agents such as infliximab (IFX, commercialized at May 2002, Mitsubishi Tanabe Pharma Corporation, Osaka, Japan), are highly effective in the induction and maintenance of remission in IBD and have remarkably improved patients’ quality of life [1, 2]. Here, TNF is linked to inflammatory bowel disease.